Education
About Us
Working with TipRanks
Follow Us
Universe Pharmaceuticals (UPC)
NASDAQ:UPC
Total Valuation
Universe Pharmaceuticals has a market cap or net worth of $1.36M. The enterprise value is ―.
Market Cap$1.36M
Enterprise Value―
Share Statistics
Universe Pharmaceuticals has 216,530 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding216,530
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Universe Pharmaceuticals’s return on equity (ROE) is -0.16 and return on invested capital (ROIC) is -12.54%.
Return on Equity (ROE)-0.16
Return on Assets (ROA)-0.12
Return on Invested Capital (ROIC)-12.54%
Return on Capital Employed (ROCE)-0.09
Revenue Per Employee143.59K
Profits Per Employee-27.39K
Employee Count225
Asset Turnover0.61
Inventory Turnover6.58
Valuation Ratios
The current PE Ratio of Universe Pharmaceuticals is -8.38. Universe Pharmaceuticals’s PEG ratio is 0.01.
PE Ratio-8.38
PS Ratio0.00
PB Ratio0.45
Price to Fair Value1.31
Price to FCF0.98
Price to Operating Cash Flow15.83
PEG Ratio0.01
Income Statement
In the last 12 months, Universe Pharmaceuticals had revenue of 32.31M and earned -6.16M in profits. Earnings per share was -1.70.
Revenue32.31M
Gross Profit10.32M
Operating Income-3.53M
Pretax Income-3.85M
Net Income-6.16M
EBITDA-3.22M
Earnings Per Share (EPS)-1.70
Cash Flow
In the last 12 months, operating cash flow was -6.07M and capital expenditures -111.18K, giving a free cash flow of -6.18M billion.
Operating Cash Flow-6.07M
Free Cash Flow-6.18M
Free Cash Flow per Share-28.55
Dividends & Yields
Universe Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.98
52-Week Price Change-99.60%
50-Day Moving Average4.30
200-Day Moving Average341.77
Relative Strength Index (RSI)60.25
Average Volume (3m)636.64K
Important Dates
Universe Pharmaceuticals upcoming earnings date is Aug 4, 2025, TBA Not Confirmed.
Last Earnings DateFeb 4, 2025
Next Earnings DateAug 4, 2025
Ex-Dividend Date―
Financial Position
Universe Pharmaceuticals as a current ratio of 2.68, with Debt / Equity ratio of 13.87%
Current Ratio2.68
Quick Ratio2.43
Debt to Market Cap0.11
Net Debt to EBITDA-0.06
Interest Coverage Ratio-22.49
Taxes
In the past 12 months, Universe Pharmaceuticals has paid 2.31M in taxes.
Income Tax2.31M
Effective Tax Rate-0.60
Enterprise Valuation
Universe Pharmaceuticals EV to EBITDA ratio is -16.13, with an EV/FCF ratio of 48.19.
EV to Sales1.60
EV to EBITDA-16.13
EV to Free Cash Flow48.19
EV to Operating Cash Flow46.29
Balance Sheet
Universe Pharmaceuticals has $11.39M in cash and marketable securities with $6.51M in debt, giving a net cash position of -$4.88M billion.
Cash & Marketable Securities$11.39M
Total Debt$6.51M
Net Cash-$4.88M
Net Cash Per Share-$22.54
Tangible Book Value Per Share$10.86
Margins
Gross margin is 31.93%, with operating margin of -10.92%, and net profit margin of -19.08%.
Gross Margin31.93%
Operating Margin-10.92%
Pretax Margin-11.91%
Net Profit Margin-19.08%
EBITDA Margin-9.95%
EBIT Margin-11.43%
Analyst Forecast
The average price target for Universe Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―